EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
EXOZYMES INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.00−0.09 (-2.20%)
Close on Oct 19, 2026
- Market cap
- $34.64M
- P/E (TTM)
- –
- Dividend yield
- –
Exozymes statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Exozymes | Industry median |
|---|---|---|
| Market Cap | $37.13M | $166.30M |
| Enterprise Value | $31.47M | $88.19M |
| PB Ratio | 10.16 | 2.03 |
| P/TBV Ratio | 10.16 | 2.29 |
Income (trailing twelve months)
| Measure | Exozymes | Industry median |
|---|---|---|
| Operating Income | -$10.56M | -$21.40M |
| Pretax Income | -$10.30M | -$14.34M |
| Net Income | -$10.19M | -$22.46M |
| EBITDA | -$10.56M | -$16.91M |
| EPS (Diluted) | -$1.20 | -$0.83 |
Returns
| Measure | Exozymes | Industry median |
|---|---|---|
| Return on Equity (ROE) | -187.2% | -53.2% |
| Return on Assets (ROA) | -115.4% | -40.9% |
| Return on Capital Employed (ROCE) | -165.9% | -38.1% |
Balance sheet
| Measure | Exozymes | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.65M | $61.43M |
| Net Cash (Debt) | $5.65M | $15.35M |
| Net Cash Per Share | $0.61 | $0.66 |
| Equity (Book Value) | $3.65M | $49.09M |
| Book Value Per Share | $0.39 | $1.37 |
| Tangible Book Value | $3.65M | $23.52M |
| Working Capital | $4.55M | $76.81M |
Financial position
| Measure | Exozymes | Industry median |
|---|---|---|
| Current Ratio | 3.81 | 3.34 |
| Quick Ratio | 3.49 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Exozymes | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.00M | -$12.35M |
| Capital Expenditures | -$145.90K | -$1.08M |
| Free Cash Flow | -$7.14M | -$20.22M |
| FCF Per Share | -$0.77 | -$0.42 |
Efficiency
| Measure | Exozymes | Industry median |
|---|---|---|
| Profits Per Employee | -$318.47K | -$703.34K |
| Employee Count | 32 | 74 |
Dividends and yields
| Measure | Exozymes | Industry median |
|---|---|---|
| Earnings Yield | -27.4% | -23.3% |
| FCF Yield | -19.2% | -8.72% |
Shares
| Measure | Exozymes | Industry median |
|---|---|---|
| Shares Outstanding | 9,281,360 | 58,127,000 |
| Shares Change (YoY) | 11.2% | 10.9% |
| Shares Change (QoQ) | 9.46% | 0.54% |
| Float | 2,664,740 | 49,136,700 |
| Shares Held by Insiders | 71.3% | 11.6% |
| Shares Held by Institutions | 1.34% | 59.4% |
Scores
| Measure | Exozymes | Industry median |
|---|---|---|
| Altman Z-Score | -3.16 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Exozymes's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.